Featured 13F manager
DAFNA Capital Management LLC Nathan Fischel
Los Angeles, CA 20 processed 13Fs on this site · 2021 Q3–2026 Q2
- $524M
- 88 Positions
- 2026 Q2
- +19.1% QoQ
- Top 5 40.2%
Nathan Fischel files DAFNA Capital Management LLC as a Form 13F. The latest book is 2026 Q2 at $524M, up 19.1% QoQ, led by Revolution Medicines, Spdr S&P Biotech ETF, and Compass Pathways.
Portfolio
top 5 40.2% · top 10 56.2%
- RVMD - Revolution Medicines 20.1%
- XBI - Spdr S&P Biotech ETF 5.9%
- CMPS - Compass Pathways 5.4%
- STXS - Stereotaxis 4.5%
- NKTR - Nektar Therapeutics 4.3%
- DNLI - Denali Therapeutics 3.6%
- IDYA - Ideaya Biosciences 3.5%
- ATRC - Atricure 3.2%
- XENE - Xenon Pharmaceuticals 2.9%
- CYTK - Cytokinetics 2.8%
- RCUS - Arcus Biosciences 2.6%
- ASND - Ascendis Pharma A/S 2.5%
- Other 38.7%
AUM over time
Book
| STXS - Stereotaxis | 10.51% | Hold | 13,680,554 | $3.11 | $43M | — | — |
| XBI - Spdr S&P Biotech ETF | 9.94% | Reduce −3.4% | 401,505 | $100.20 | $40M | −14,000 | +$6M |
| RVMD - Revolution Medicines | 7.58% | Reduce −3.0% | 657,176 | $46.70 | $31M | −20,000 | +$6M |
| CYTK - Cytokinetics | 5.36% | Reduce −0.8% | 394,940 | $54.96 | $22M | −3,160 | +$9M |
| ATRC - Atricure | 5.16% | Hold | 592,273 | $35.25 | $21M | — | — |
| Merus Bv | 5.13% | Reduce −44.7% | 220,451 | $94.15 | $21M | −178,353 | −$222K |
| NDAQ - Ishares Nasdaq Biotech Indx | 3.66% | Hold | 102,500 | $144.37 | $15M | — | — |
| IDYA - Ideaya Biosciences | 3.63% | Reduce −12.8% | 539,923 | $27.21 | $15M | −79,167 | +$2M |
| AXGN - Axogen | 3.27% | Add +0.1% | 742,282 | $17.84 | $13M | +500 | +$5M |
| XENE - Xenon Pharmaceuticals | 2.86% | Hold | 287,939 | $40.15 | $12M | — | — |
| NBIX - Neurocrine Biosciences | 2.45% | Hold | 70,615 | $140.38 | $10M | — | — |
| RCUS - Arcus Biosciences | 2.11% | Hold | 627,626 | $13.60 | $9M | — | — |
| SNDX - Syndax Pharmaceuticals | 1.90% | Reduce −7.9% | 500,702 | $15.38 | $8M | −42,900 | +$3M |
| DAWNGBX — | 1.74% | Add +13.6% | 999,163 | $7.05 | $7M | +120,000 | +$1M |
| ASND - Ascendis Pharma A/S | 1.63% | Reduce −54.4% | 33,177 | $198.81 | $7M | −39,500 | −$6M |
| Kalvista Pharmaceuticals | 1.27% | Reduce −27.3% | 422,731 | $12.18 | $5M | −159,026 | −$1M |
| BCAX - Bicara Therapeutics | 1.24% | Hold | 317,001 | $15.79 | $5M | — | — |
| INGN - Inogen | 1.22% | Hold | 605,625 | $8.17 | $5M | — | — |
| CMPS - Compass Pathways | 1.15% | Hold | 811,046 | $5.73 | $5M | — | — |
| LKFT - Galapagos | 1.11% | Hold | 130,175 | $34.64 | $5M | — | — |
| DXCM - Dexcom | 1.09% | Hold | 65,552 | $67.29 | $4M | — | — |
| TNDM - Tandem Diabetes Care | 1.07% | Add +20.7% | 355,208 | $12.14 | $4M | +61,000 | −$1M |
| KURA - Kura Oncology | 1.01% | Hold | 463,368 | $8.85 | $4M | — | — |
| ALKS - Alkermes | 1.00% | Add +29.9% | 134,748 | $30.00 | $4M | +31,000 | +$1M |
| STOK - Stoke Therapeutics | 0.99% | Reduce −66.2% | 169,791 | $23.50 | $4M | −332,181 | −$2M |
| SLNOEUR - Soleno Therapeutics | 0.89% | New | 53,000 | $67.60 | $4M | +53,000 | +$4M |
| BHVN - Biohaven | 0.87% | Hold | 235,235 | $15.01 | $4M | — | — |
| EWTX - Edgewise Therapeutics | 0.86% | Reduce −10.2% | 213,736 | $16.22 | $3M | −24,404 | +$345K |
| PRQR - Proqr Therapeutics | 0.82% | Hold | 1,567,561 | $2.13 | $3M | — | — |
| LRMR - Larimar Therapeutics | 0.82% | Add +176.7% | 1,027,764 | $3.23 | $3M | +656,330 | +$2M |
| CMPX - Compass Therapeutics | 0.82% | Add +79.7% | 946,661 | $3.50 | $3M | +420,001 | +$2M |
| MLYS - Mineralys Therapeutics | 0.78% | Reduce −77.5% | 83,490 | $37.92 | $3M | −288,033 | −$2M |
| NKTR - Nektar Therapeutics | 0.77% | Add +450.0% | 54,998 | $56.90 | $3M | +44,998 | +$3M |
| IMVT - Immunovant | 0.76% | Hold | 191,493 | $16.12 | $3M | — | — |
| Korro Bio | 0.72% | Add +5.4% | 60,804 | $47.89 | $3M | +3,113 | +$2M |
| AQST - Aquestive Therapeutics | 0.71% | Add +261.0% | 512,589 | $5.59 | $3M | +370,589 | +$2M |
| DNLI - Denali Therapeutics | 0.60% | Hold | 168,500 | $14.52 | $2M | — | — |
| LXEO - Lexeo Therapeutics | 0.59% | Reduce −5.3% | 358,083 | $6.64 | $2M | −20,000 | +$858K |
| ALEC - Alector | 0.58% | Reduce −12.6% | 798,351 | $2.96 | $2M | −114,577 | +$1M |
| CATBUSD - Astria Therapeutics | 0.58% | Reduce −1.5% | 319,775 | $7.28 | $2M | −5,000 | +$587K |
| RAPP - Rapport Therapeutics | 0.55% | New | 75,000 | $29.70 | $2M | +75,000 | +$2M |
| TELA - Tela Bio | 0.53% | Hold | 1,441,029 | $1.49 | $2M | — | — |
| PODD - Insulet | 0.52% | Reduce −30.6% | 6,870 | $308.73 | $2M | −3,030 | −$989K |
| Mediwound | 0.51% | Add +76.2% | 113,612 | $18.02 | $2M | +49,133 | +$798K |
| ARAY - Accuray | 0.50% | Hold | 1,222,358 | $1.67 | $2M | — | — |
| Immatics | 0.49% | Reduce −4.1% | 235,000 | $8.52 | $2M | −10,000 | +$684K |
| ALLO - Allogene Therapeutics | 0.42% | Hold | 1,380,118 | $1.24 | $2M | — | — |
| VKTX - Viking Therapeutics | 0.42% | Hold | 64,516 | $26.28 | $2M | — | — |
| BCRX - Biocryst Pharmaceuticals | 0.41% | Hold | 218,255 | $7.59 | $2M | — | — |
| GPCR - Structure Therapeutics | 0.41% | Hold | 59,000 | $28.00 | $2M | — | — |
| MBX - Mbx Biosciences | 0.37% | New | 85,000 | $17.50 | $1M | +85,000 | +$1M |
| SPRY - Ars Pharmaceuticals | 0.35% | New | 140,500 | $10.05 | $1M | +140,500 | +$1M |
| ALGN - Align Technology | 0.34% | Hold | 11,000 | $125.22 | $1M | — | — |
| Keros Therapeutics | 0.32% | Reduce −38.1% | 80,716 | $15.82 | $1M | −49,600 | −$463K |
| INSP - Inspire Medical Systems | 0.32% | New | 17,200 | $74.20 | $1M | +17,200 | +$1M |
| ORIC - Oric Pharmaceuticals | 0.31% | Reduce −22.6% | 104,671 | $12.00 | $1M | −30,600 | −$117K |
| BDTX — | 0.29% | Reduce −34.8% | 307,070 | $3.79 | $1M | −163,930 | −$4K |
| OBIO - Orchestra Biomed | 0.22% | New | 363,636 | $2.48 | $902K | +363,636 | +$902K |
| BWAY - Brainsway | 0.21% | Reduce −55.2% | 56,966 | $15.07 | $858K | −70,185 | −$814K |
| IPSC - Century Therapeutics | 0.21% | Hold | 1,704,232 | $0.4980 | $849K | — | — |
| ERAS - Erasca | 0.19% | Hold | 350,000 | $2.18 | $763K | — | — |
| Polypid | 0.17% | Hold | 207,900 | $3.34 | $693K | — | — |
| BNTX - Biontech Se | 0.17% | Hold | 7,000 | $98.62 | $690K | — | — |
| CLDX — | 0.16% | New | 24,518 | $25.87 | $634K | +24,518 | +$634K |
| FHTX - Foghorn Therapeutics | 0.15% | Reduce −57.8% | 126,859 | $4.89 | $620K | −173,593 | −$792K |
| URGN - Urogen Pharma | 0.14% | Reduce −92.1% | 27,515 | $19.95 | $549K | −322,000 | −$4M |
| NGNE - Neurogene | 0.13% | Reduce −40.6% | 30,375 | $17.33 | $526K | −20,721 | −$237K |
| BCYC - Bicycle Therapeutics | 0.12% | Hold | 64,492 | $7.74 | $499K | — | — |
| ADCT - Adc Therapeutics SA | 0.12% | Hold | 122,081 | $4.00 | $488K | — | — |
| Compugen | 0.10% | Hold | 272,402 | $1.47 | $400K | — | — |
| Sutro Biopharma | 0.09% | Hold | 437,079 | $0.8684 | $380K | — | — |
| AUTL - Autolus Therapeutics | 0.07% | Reduce −57.9% | 179,316 | $1.63 | $292K | −246,300 | −$678K |
| Biomx | 0.05% | Hold | 401,136 | $0.5250 | $211K | — | — |
| APRE - Aprea Therapeutics | 0.05% | Hold | 137,174 | $1.48 | $202K | — | — |
Showing top 50 of 74 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2025 Q2
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Blueprint Medicines | 5.97% | Exit | 0 | $128.18 | $22M | −168,763 | −$22M |
| Iteos Therapeutics | 0.39% | Exit | 0 | $9.97 | $1M | −140,847 | −$1M |
| Vyne Therapeutics | 0.29% | Exit | 0 | $1.65 | $1M | −636,103 | −$1M |
| Gossamer Bio | 0.29% | Exit | 0 | $1.23 | $1M | −849,921 | −$1M |
| PVLA - Palvella Therapeutics | 0.27% | Exit | 0 | $22.54 | $977K | −43,348 | −$977K |
| Adicet Bio | 0.09% | Exit | 0 | $0.6093 | $329K | −540,000 | −$329K |
| PRCT - Procept Biorobotics | 0.05% | Exit | 0 | $57.67 | $173K | −3,000 | −$173K |
| IFRX - Inflarx | 0.04% | Exit | 0 | $0.7900 | $158K | −200,000 | −$158K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 88 | $524M | +19.1% | 13F-HR | 8/14/2026 | 000138993326000006 |
| 2026 Q1 | 83 | $440M | +2.1% | 13F-HR | 5/15/2026 | 000138993326000004 |
| 2025 Q4 | 77 | $431M | +6.4% | 13F-HR | 2/17/2026 | 000138993326000002 |
| 2025 Q3 | 75 | $405M | +11.9% | 13F-HR | 11/14/2025 | 000138993325000008 |
| 2025 Q2 | 76 | $362M | +2.5% | 13F-HR | 8/14/2025 | 000138993225000011 |
| 2025 Q1 | 83 | $353M | −10.2% | 13F-HR | 5/15/2025 | 000138993325000002 |
| 2024 Q4 | 82 | $393M | −7.1% | 13F-HR | 2/14/2025 | 000138993225000004 |
| 2024 Q3 | 84 | $423M | +1.0% | 13F-HR | 11/14/2024 | 000138993224000020 |
| 2024 Q2 | 83 | $419M | −4.6% | 13F-HR | 8/14/2024 | 000138993224000016 |
| 2024 Q1 | 72 | $439M | +5.3% | 13F-HR | 5/15/2024 | 000138993224000012 |
| 2023 Q4 | 76 | $417M | +29.9% | 13F-HR | 2/14/2024 | 000138993224000004 |
| 2023 Q3 | 75 | $321M | −12.3% | 13F-HR | 11/14/2023 | 000138993223000010 |
| 2023 Q2 | 73 | $366M | +9.6% | 13F-HR | 8/14/2023 | 000138993323000008 |
| 2023 Q1 | 72 | $334M | −5.9% | 13F-HR | 5/15/2023 | 000138993323000006 |
| 2022 Q4 | 79 | $355M | −4.6% | 13F-HR | 2/14/2023 | 000138993323000002 |
| 2022 Q3 | 87 | $372M | +1.4% | 13F-HR | 11/14/2022 | 000138993322000010 |
| 2022 Q2 | 90 | $367M | −4.4% | 13F-HR | 8/15/2022 | 000138993322000008 |
| 2022 Q1 | 94 | $384M | −3.5% | 13F-HR | 5/16/2022 | 000138993322000006 |
| 2021 Q4 | 87 | $398M | +5.6% | 13F-HR | 2/14/2022 | 000138993322000002 |
| 2021 Q3 | 80 | $377M | — | 13F-HR | 11/15/2021 | 000138993321000011 |
About
DAFNA Capital Management LLC
20 processed 13Fs on this site · 2021 Q3–2026 Q2